Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Mifomelatide (TCMCB07) in Healthy Volunteers
NCT05529849Phase 1Completed
- Sponsor
- Endevica Bio
- Start
- Jul 2022
- Primary completion
- Dec 2022
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in cancer cachexia comparing Mifomelatide with Placebo (2 arms). Primary endpoints: Number of people with an Adverse Event Assessment at 6 Months, Number of participants with abnormal vital signs at 6 Months and 3 more. Started Jul 2022; status: completed.
02
Drugs
mifomelatide
03
Conditions
cancer cachexia
Beyond the preview
Go deeper on NCT05529849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05529849.